CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 19 enrolled
Drug / intervention
Guardian Sensor (3)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04020822
NCT04020822N/ACompleted
CompareCT.gov

Feasibility Study of New Subcutaneous Glucose Sensor With Recording Devices - Phase 3 Group

Medtronic MiniMed, Inc.·interventional·Posted Jul 16, 2019·Updated Sep 16, 2020

In Brief

A clinical study evaluating Guardian Sensor (3) for Type 1 Diabetes and Type 2 Diabetes. Completed, enrolled 19 participants across 2 sites.

Detailed Summary

The purpose of Phase 3 Group is to evaluate the impact of acetaminophen on the performance of Guardian Sensor (3) during 11 days of wear (approximately 264 hours) in subjects with insulin requiring diabetes,18-75 years of age.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes, Type 2 Diabetes
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedJul 16, 2019
Enrollment StartJul 29, 2019
Primary CompletionAug 27, 2019
TodayJul 2, 2026
Enrollment to primary: 28 daysPosted 7.0 years ago

Interventions

Guardian Sensor (3)device

Guardian Sensor (3) connected to Guardian Link (3) Transmitter and/or Guardian Connect Transmitter.